All Updates

All Updates

icon
Filter
Funding
Greenwich LifeSciences raises USD 2.5 million via private placement for clinical development and working capital needs
Precision Medicine
Jun 14, 2024
This week:
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Cohesity enhances Gaia, its AI assistant, with visual data exploration and expanded data sources
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Finzly launches FedNow service through BankOS platform in AWS marketplace
FinTech Infrastructure
Oct 22, 2024
Product updates
Runway launches Act-One for AI facial expression motion capture
Generative AI Applications
Oct 22, 2024
Product updates
Ideogram launches Canvas for image manipulation and generation
Generative AI Applications
Oct 22, 2024
Partnerships
UiPath partners with Inflection AI to integrate AI solutions for enterprises
Generative AI Applications
Oct 22, 2024
Precision Medicine

Precision Medicine

Jun 14, 2024

Greenwich LifeSciences raises USD 2.5 million via private placement for clinical development and working capital needs

Funding

  • Greenwich LifeSciences has secured approximately USD 2.5 million in private placement via a securities purchase agreement with its CEO. The transaction includes the sale and purchase of 174,825 shares at USD 14.30 per share.

  • The proceeds will be used for clinical development and supporting the company's working capital.

  • Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of immunotherapies aimed at preventing breast cancer recurrences. The company's primary candidate, GP2, is derived from the HER2/neu protein and is designed to target and prevent the recurrence of breast cancer in patients who have undergone surgery. GP2 has demonstrated promising results in a Phase IIb clinical trial and is currently being evaluated in the Flamingo-01 Phase III clinical trial.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.